Related Experiment Video
Updated: Jan 4, 2026
11:17
Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
17.0K
Long-Acting Growth Hormone Preparations - Current Status and Future Considerations.
Bradley S Miller1, Eric Velazquez1, Kevin C J Yuen2
1Division of Endocrinology, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.
The Journal of Clinical Endocrinology and Metabolism
|November 3, 2019
Summary
New long-acting growth hormone (LAGH) preparations offer less frequent injections for growth hormone deficiency (GHD). Short-term studies show promising efficacy and safety, but long-term data are needed.
Area of Science:
- Endocrinology
- Pharmacology
- Pediatric Endocrinology
Background:
- Long-acting growth hormone (LAGH) preparations are under development to improve patient adherence.
- The unique action profile of LAGH raises questions regarding clinical monitoring and long-term outcomes.
Purpose of the Study:
- To review current literature and meeting proceedings on LAGH preparations.
- To assess the current status, efficacy, safety, and future considerations for LAGH therapy.
Main Methods:
- Review of recent scientific literature and conference proceedings concerning LAGH.
- Analysis of data from randomized, controlled clinical trials of LAGH preparations.
Main Results:
- Multiple LAGH preparations are in development, enabling reduced injection frequency (weekly to monthly).
- Short-term trials indicate non-inferiority to daily recombinant human GH (rhGH) regarding growth velocity and body composition in GHD.
- No significant short-term adverse events related to LAGH have been reported.
Conclusions:
- LAGH preparations show promise for short-term efficacy and safety in GHD treatment.
- Further research is required to understand the long-term safety and efficacy, optimal monitoring strategies, and cost-effectiveness of LAGH.
- Long-term surveillance is essential to address clinical questions and determine LAGH's role in replacing daily rhGH.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
588
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
588
01:24Glucagon-like Receptor Agonists
792
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
792
01:16Insulin: Dosing Regimen and Adverse Effects
626
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
626
01:28Drug Products: Biologics, Biosimilars and Interchangeables
208
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
208
01:25Insulin: Biosynthesis, Chemistry, and Preparation
1.1K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.1K
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
152
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
152